Pharma Update

Roche R&D has multiple proven strengths Strategy and portfolio • Operating . model and structure • Commitment to scientific excellence and discovery of novel modalities (e.g. ADCs, bispecifics) Ability to expand successfully into new therapeutic areas Roche Autonomous early stage R&D units gRED, PRED and Chugai, specialized in their respective domains Successfully launched 20 NMEs in the last 8 years. • Talent, culture Breadth and depth of expertise across a range of disease areas 50 and mindset • Leaders in emerging areas such as computational biology, new disease models, and protein engineering 0101 00101 0101 Capabilities, tech, and Al • Strong organizational loyalty, external reputation and ability to attract top scientific talent • Leveraging thought leadership in generative Al and deep learning approaches NME=new molecular entity; Al-artifical intelligence; ADC=antibody drug conjugate 20 20

View entire presentation